The Efficacy and Safety of Adjuvant Immunotherapy After Pathological Complete Response Following Neoadjuvant Chemoimmunotherapy in Patients with Resectable NSCLC
Clinical trial NCT06243679 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06243679
- Sponsor
- Xiangya Hospital of Central South University
- Status
- ACTIVE_NOT_RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2020-07-01
- Primary completion
- 2027-09-01
- Enrollment
- 100
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.